DCLK1 and neoplasm: Intravenous injections of DCLK1-directed CAR T-cells have been shown to reduce tumor size in tumor-bearing mice, strongly suggesting that DCLK1-based CAR T-cells inhibit CRC tumor growth in vivo without obvious cytotoxicity to normal tissues (110).